Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Immunogenicity of APL-10456-Vaccine in Healthy Volunteers

NCT07399132 is registered in ClinicalTrials.gov with Apollo Therapeutics Ltd as lead sponsor.

NCT NCT07399132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07399132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Immunogenicity of APL-10456-Vaccine in Healthy Volunteers
Lead sponsor
Apollo Therapeutics Ltd
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 16, 2026
Completion date
May 18, 2027
Enrollment
144 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rhinovirus